reports
- GlobalData Department
Kobayashi Pharmaceutical Co Ltd (4967) - Medical Equipment - Deals and...
Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body warmers. It also offers health food products, dietary food products, nutritional supplements, skin care products, medical equipment, devices and ventilators to medical institutes and hospitals, transp...
- Shanshan Wei
- CFA
- Shanshan Wei
- CFA
Kobayashi will maintain its edge in Japan and develop more “hidden p...
Narrow-moat Kobayashi Pharmaceutical announced the acquisition of Jiangsu Zhongdan Pharmaceutical, a drug manufacturer in Jiangsu, China, aiming to accelerate the expansion of its over-the-counter drug business in the country. The acquisition is expected to be completed by June 30. While the price was not disclosed, we believe the deal itself will have only a marginal impact on Kobayashi’s earnings and return on investment, given that the revenue of the targeted firm is less than 1% of Kobayas...
- Shanshan Wei
- CFA
Kobayashi Acquires Drug Manufacturer in China to Reinforce OTC Busines...
Narrow-moat Kobayashi Pharmaceutical announced the acquisition of Jiangsu Zhongdan Pharmaceutical, a drug manufacturer in Jiangsu, China, aiming to accelerate the expansion of its over-the-counter drug business in the country. The acquisition is expected to be completed by June 30. While the price was not disclosed, we believe the deal itself will have only a marginal impact on Kobayashi’s earnings and return on investment, given that the revenue of the targeted firm is less than 1% of Kobayas...
- Shanshan Wei
- CFA
Kobayashi will maintain its edge in Japan and develop more “hidden p...
Narrow-moat Kobayashi posted a healthy full-year result with revenue and operating income increasing by 8.3% and 24.3% year over year, which are in line with our expectations. Supported by the company’s established brand equity in the niche consumer categories, which is our main moat source, the firm’s 7.3% sales growth in the domestic personal care division again outperformed the industry’s growth of 2%-3%. The growth from new products which launched within the past four years, inbound sa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.